Alembic Pharmaceuticals Limited (APLLTD) AI Stock Analysis

• Market Cap: ₹166.32B
• Dividend Yield: 1.3%
• Average Volume (3M): 9.79K
• Price to Earnings (P/E): 26.2
• Beta (1Y): 0.88
• Revenue Growth: 11.42%
• EPS Growth: -1.91%
• Country: IN
• Employees: 14,858
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 9.40
• Shares Outstanding: 196,563,130
• 10 Day Avg. Volume: 3,852
• 30 Day Avg. Volume: 9,793
• PEG Ratio: -5.74
• Price to Book (P/B): 3.40
• Price to Sales (P/S): 2.64
• P/FCF Ratio: -37.06
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹915.00
• Price Target Upside: -1.64% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): 35.42
• Revenue Forecast (FY): ₹74.10B

• Rating: 60 Neutral
• Price Target: ₹1,021.00 ▲(9.75% Upside)

Alembic Pharmaceuticals presents a mixed outlook. Strong revenue growth and profitability are offset by cash flow challenges and rising leverage. Technical indicators suggest bearish momentum, and the stock's valuation appears high. The absence of earnings call data limits insights into future guidance.

Positive Factors

Revenue Growth

Consistent revenue growth indicates a robust market presence and effective product strategy, supporting long-term business expansion.

Market Expansion

Expanding into regulated markets enhances revenue potential and diversifies risk, strengthening Alembic's competitive position.

Profitability

Improved profit margins reflect effective cost management and operational efficiency, contributing to sustainable financial health.

Negative Factors

Cash Flow Challenges

Declining free cash flow can limit investment capacity and operational flexibility, posing risks to long-term growth and stability.

Rising Leverage

Increased leverage may strain financial resources and increase risk, potentially impacting the company's ability to finance future growth.

Net Profit Margin Fluctuations

Fluctuating net profit margins suggest challenges in maintaining consistent profitability, which could affect long-term financial stability.

Alembic Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Alembic Pharmaceuticals Limited (APLLTD) is a leading global pharmaceutical company based in India, specializing in the development, manufacturing, and marketing of a wide range of generic and branded pharmaceutical products. The company operates primarily in the sectors of formulations and active pharmaceutical ingredients (APIs), offering a diverse portfolio that includes medications for various therapeutic areas such as cardiology, gynecology, and oncology. APLLTD is committed to quality and innovation, ensuring compliance with international regulatory standards while expanding its presence in both domestic and international markets.

How the Company Makes Money

Alembic Pharmaceuticals generates revenue primarily through the sale of generic and branded pharmaceuticals, with key revenue streams coming from its formulations and API segments. The company earns significant income from its extensive portfolio of generic drugs, which are marketed to various healthcare providers and institutions. Additionally, APLLTD engages in partnerships and collaborations with other pharmaceutical companies for research and development, licensing agreements, and distribution, further enhancing its revenue potential. The company's focus on expanding its global footprint, particularly in regulated markets such as the United States and Europe, alongside its commitment to quality and regulatory compliance, contributes to its financial success.

Alembic Pharmaceuticals Limited Financial Statement Overview

Summary

Alembic Pharmaceuticals shows strong revenue growth and profitability improvements, but faces challenges in cash flow management and rising leverage. Continued focus on cost control and cash conversion is crucial.

Income Statement

Alembic Pharmaceuticals shows strong gross profit margins over the years, with a notable improvement in revenue and EBIT margins in the recent period. However, the net profit margin has experienced some fluctuations, indicating potential cost management issues. The consistent revenue growth rate is a positive indicator of the company's expanding market presence.

Balance Sheet

The balance sheet reveals a healthy equity base, reflected in a strong equity ratio. The debt-to-equity ratio increased in the latest period, which could indicate rising leverage and potential risk. However, the return on equity remains robust, suggesting efficient use of shareholders' funds.

Cash Flow

The cash flow statement highlights a decline in free cash flow due to increased capital expenditures. The operating cash flow to net income ratio is lower, indicating less cash generation from operations. The negative free cash flow to net income ratio suggests challenges in converting profits into cash.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	68.21B	66.72B	62.29B	56.53B	53.06B	53.93B
Gross Profit	49.27B	47.91B	44.33B	38.78B	38.08B	40.53B
EBITDA	10.32B	9.89B	9.14B	6.96B	8.59B	14.66B
Net Income	6.03B	5.83B	6.16B	3.42B	5.21B	11.46B
Balance Sheet
Total Assets	0.00	77.73B	64.46B	61.83B	71.22B	67.09B
Cash, Cash Equivalents and Short-Term Investments	834.80M	901.00M	1.20B	754.80M	610.90M	2.85B
Total Debt	0.00	12.57B	5.13B	7.22B	7.17B	5.84B
Total Liabilities	-51.90B	25.83B	16.27B	18.12B	18.84B	16.42B
Stockholders Equity	51.90B	51.91B	48.18B	43.70B	52.38B	50.67B
Cash Flow
Free Cash Flow	0.00	-4.76B	4.76B	2.81B	1.27B	8.04B
Operating Cash Flow	0.00	879.70M	8.03B	7.24B	5.52B	14.63B
Investing Cash Flow	0.00	-5.68B	-3.21B	-4.48B	-3.72B	-8.39B
Financing Cash Flow	0.00	4.44B	-4.38B	-2.62B	-2.17B	-5.97B

Alembic Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 930.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:APLLTD, the sentiment is Negative. The current price of 930.3 is above the 20-day moving average (MA) of 891.56, above the 50-day MA of 910.16, and above the 200-day MA of 922.56, indicating a bearish trend. The MACD of -15.25 indicates Positive momentum. The RSI at 29.44 is Positive, neither overbought nor oversold. The STOCH value of 5.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:APLLTD.

Alembic Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATCOPHARM	76 Outperform	₹165.15B	10.73	―	0.57%	-3.79%	-20.88%
MARKSANS	70 Neutral	₹84.83B	24.12	―	0.43%	14.80%	1.35%
JBCHEPHARM	66 Neutral	₹279.97B	38.79	―	0.87%	10.25%	17.01%
GLAXO	63 Neutral	₹438.49B	45.90	―	2.09%	4.17%	41.51%
JUBLPHARMA	62 Neutral	₹169.15B	35.21	―	0.48%	10.09%	-19.40%
APLLTD	60 Neutral	₹166.32B	26.22	―	1.30%	11.42%	-1.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Alembic Pharmaceuticals Limited Corporate Events

Alembic Pharmaceuticals Schedules Investor Meeting with ICICI Prudential

Alembic Pharmaceuticals Limited has announced a scheduled one-on-one meeting with ICICI Prudential Pharma Fund on December 10, 2025, in Mumbai. This meeting indicates the company’s proactive engagement with investors, which could enhance its visibility and strengthen investor relations, potentially impacting its market positioning positively.

Alembic Pharmaceuticals Gains USFDA Approval for Diltiazem Tablets

Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Diltiazem Hydrochloride Tablets USP in various dosages. This approval marks a significant milestone for Alembic, enhancing its portfolio of USFDA-approved products and strengthening its position in the global pharmaceutical market. The approval is expected to positively impact the company’s operations and market presence, offering stakeholders potential growth opportunities.

Alembic Pharmaceuticals Initiates Transfer of Unclaimed Shares

Alembic Pharmaceuticals Limited has announced a newspaper advertisement regarding the transfer of shares from its Unclaimed Suspense Account to the claimant’s demat account. This move is part of the company’s compliance with regulatory requirements, ensuring that unclaimed shares are properly managed and transferred to rightful owners, thereby maintaining transparency and accountability in its operations.

Alembic Pharmaceuticals Schedules Post-Results Conference Call

Alembic Pharmaceuticals Limited has announced a post-results conference call scheduled for November 4, 2025, aimed at analysts and institutional investors. The call will discuss the company’s unaudited financial results for the second quarter of the fiscal year 2026, with participation from key members of the senior management team. This initiative underscores the company’s commitment to transparency and engagement with its stakeholders, potentially impacting investor confidence and market positioning.

Alembic Pharmaceuticals Updates Registrar’s Email for Improved Communication

Alembic Pharmaceuticals Limited has announced a change in the email address for its Registrar and Share Transfer Agent, MUFG Intime India Private Limited. This update, effective from October 1, 2025, introduces a new generic email ID for investors, which will be used across all companies serviced by MIIPL, potentially streamlining communication and improving investor relations.